New Wharton’s Jelly MSC Study: Why Cell Quality Testing Matters
Key Takeaways A 2026 study in Scientific Reports followed 49 patients with steroid-resistant GvHD treated with Wharton’s jelly MSCs at four hospitals in Spain. At day 28, 71.4% of patients responded to treatment. One-year survival reached 55.1%. Batches that scored above 70% on a potency test produced far better outcomes,
June 30, 2026
No Comments
